SCHEMBL10189263

SCHEMBL10189263

COc1ccc(-c2csnc2-c2cc(C)c3c(c2)OCO3)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.45
KIT P10721 2/20 0.36
FYN P06241 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
HSD17B1 P14061 1/20 0.34
HSD17B2 P37059 1/20 0.34
TDO2 P48775 2/20 0.33
PIK3CA P42336 1/20 0.33
POLQ O75417 1/20 0.33
RPS6KA3 P51812 1/20 0.33
CASP3 P42574 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
APP P05067 1/20 0.32
ACHE P22303 1/20 0.32
IDO1 P14902 1/20 0.32
PIK3CD O00329 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL616825 0.89 ALDH1A1 (0.41) CYP2A6KITFYNTDO2ACHE
SCHEMBL10189278 0.83 UGT1A1 (0.41)
SCHEMBL12339064 0.83 CYP2A6 (0.40) CYP2A6KITPDE3BPDE3AHSD17B1
SCHEMBL10189264 0.81 CASP3 (0.41) FYNTDO2CASP3SENP7APP
SCHEMBL10189259 0.81 TUBB4A (0.36) KIT
SCHEMBL10189266 0.80 TSHR (0.38) POLQ
SCHEMBL10189261 0.80 MAPT (0.39) APPACHE
SCHEMBL10189265 0.79 TARBP2 (0.41) POLQ
SCHEMBL10189256 0.79 FYN (0.33) KITFYNTDO2POLQAPP
SCHEMBL10189274 0.79 CFTR (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 CYP2A6 3750/4885KIT 1486/4885FYN 1940/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 CYP2A6 3750/4885KIT 1486/4885FYN 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.